trending Market Intelligence /marketintelligence/en/news-insights/trending/yemw_wph3f9d-fo8knmd5g2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Kadmon stem cell transplant complication therapy gets US FDA breakthrough status

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Kadmon stem cell transplant complication therapy gets US FDA breakthrough status

Kadmon Holdings Inc. said it received the U.S. Food and Drug Administration's breakthrough therapy designation for KD025 to treat stem cell transplant complication.

Chronic graft-versus-host disease is a common and often fatal complication following stem cell transplantation in which transplanted immune cells attack the patient's cells, leading to inflammation and damage to various organs.

The designation is based on a phase 2 study, which showed that the drug was well-tolerated and demonstrated clinical activity among the patients with the complication.

New York-based Kadmon is recruiting patients for another midstage study, named KD025-213, for adults with chronic graft-versus-host disease who have received at least two prior lines of systemic therapy.

The FDA's breakthrough therapy designation accelerates the development and review of drugs that are meant to treat a serious condition and have shown a meaningful benefit.